New risk classification adapting SCAI shock stages to patients with pulmonary embolism (RISA-PE).


Journal

Minerva cardiology and angiology
ISSN: 2724-5772
Titre abrégé: Minerva Cardiol Angiol
Pays: Italy
ID NLM: 101776555

Informations de publication

Date de publication:
24 Sep 2024
Historique:
medline: 24 9 2024
pubmed: 24 9 2024
entrez: 24 9 2024
Statut: aheadofprint

Résumé

Pulmonary embolism (PE) treatment is based on risk stratification according to European Society of Cardiology (ESC) guidelines. However, emerging therapies in acute PE may require a more granular risk classification. Therefore, the objective of the present study was to propose a new RIsk claSsification Adapting the SCAI shock stages to right ventricular failure due to acute PE (RISA-PE). This registry included consecutive intermediate-high risk (IHR) or high-risk (HR)-PE patients selected for catheter-directed interventions (CDI) from 2018 to 2023 in 15 Spanish centers (NCT06348459). Patients were grouped according to RISA-PE classification as A (right ventricular dysfunction and troponin elevation); B (A + serum lactate >2 mmol/L OR shock index ≥1); C (persistent hypotension); D (obstructive shock); and E (cardiac arrest). In-hospital adverse events were assessed to evaluate RISA-PE performance. A total of 334 patients were included (age 62.1±15.2 years, 55.7% males). The incidence of in-hospital all-cause death was progressively higher with increasing RISA-PE stage (1.2%, 6.4%, 19.0%, 25.6%, and 57.7% for stages A, B, C, D, and E, respectively, P value for linear trend<0.001). However, using the ESC classification, there was an abrupt difference between IHR- and HR-PE patients regarding mortality (4.3% vs. 29.3%, P<0.001). The incidence of in-hospital major bleeding and acute kidney injury followed a similar pattern. The user-friendly RISA-PE classification may improve the granularity in stratifying PE patients' risk and warrants evaluation in larger studies with different therapeutic approaches in order to detect its utility as a decision-making scale.

Sections du résumé

BACKGROUND BACKGROUND
Pulmonary embolism (PE) treatment is based on risk stratification according to European Society of Cardiology (ESC) guidelines. However, emerging therapies in acute PE may require a more granular risk classification. Therefore, the objective of the present study was to propose a new RIsk claSsification Adapting the SCAI shock stages to right ventricular failure due to acute PE (RISA-PE).
METHODS METHODS
This registry included consecutive intermediate-high risk (IHR) or high-risk (HR)-PE patients selected for catheter-directed interventions (CDI) from 2018 to 2023 in 15 Spanish centers (NCT06348459). Patients were grouped according to RISA-PE classification as A (right ventricular dysfunction and troponin elevation); B (A + serum lactate >2 mmol/L OR shock index ≥1); C (persistent hypotension); D (obstructive shock); and E (cardiac arrest). In-hospital adverse events were assessed to evaluate RISA-PE performance.
RESULTS RESULTS
A total of 334 patients were included (age 62.1±15.2 years, 55.7% males). The incidence of in-hospital all-cause death was progressively higher with increasing RISA-PE stage (1.2%, 6.4%, 19.0%, 25.6%, and 57.7% for stages A, B, C, D, and E, respectively, P value for linear trend<0.001). However, using the ESC classification, there was an abrupt difference between IHR- and HR-PE patients regarding mortality (4.3% vs. 29.3%, P<0.001). The incidence of in-hospital major bleeding and acute kidney injury followed a similar pattern.
CONCLUSIONS CONCLUSIONS
The user-friendly RISA-PE classification may improve the granularity in stratifying PE patients' risk and warrants evaluation in larger studies with different therapeutic approaches in order to detect its utility as a decision-making scale.

Identifiants

pubmed: 39315892
pii: S2724-5683.24.06609-2
doi: 10.23736/S2724-5683.24.06609-2
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Rocío Párraga (R)

Department of Cardiology, Hospital Universitario Clínico San Carlos, Madrid, Spain.
Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.

Carlos Real (C)

Department of Cardiology, Hospital Universitario Clínico San Carlos, Madrid, Spain.
Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.

Jesús Jiménez-Mazuecos (J)

Department of Cardiology, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.

María-Eugenia Vázquez-Álvarez (ME)

Department of Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.

Ernesto Valero (E)

Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
Department of Cardiology, Hospital Clínico Universitario, Valencia, Spain.
Instituto de Investigación Sanitaria (INCLIVA), Valencia, Spain.

Maite Velázquez (M)

Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
Department of Cardiology, Hospital Universitario 12 de Octubre, Madrid, Spain.

Daniel Tébar (D)

Department of Cardiology, Hospital Universitario La Paz (IdiPAZ), Madrid, Spain.

Neus Salvatella (N)

Department of Cardiology, Hospital del Mar, Barcelona, Spain.

Eva Rumiz (E)

Department of Cardiology, Consorcio Hospital General Universitario de Valencia, Valencia, Spain.

Valeriano Ruiz Quevedo (V)

Department of Cardiology, Hospital Universitario de Navarra, Pamplona, Spain.

Fernando Sabatel-Pérez (F)

Department of Cardiology, Hospital Universitario Clínico San Cecilio, Granada, Spain.
Department of Cardiology, Hospital Santa Ana de Motril, Granada, Spain.

Ignacio Amat-Santos (I)

Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
Department of Cardiology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.

Iñigo Lozano (I)

Department of Cardiology, Hospital Universitario Cabueñes, Gijon, Spain.

Irene Elizondo (I)

Department of Cardiology, Hospital Universitario Donostia, Gipuzkoa, Spain.

Abel Andrés-Morist (A)

Department of Cardiology, Hospital Universitario de Basurto, Bilbao, Spain.

Iván Núñez-Gil (I)

Department of Cardiology, Hospital Universitario Clínico San Carlos, Madrid, Spain.

Juan J Portero (JJ)

Department of Cardiology, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.

Nieves Gonzalo (N)

Department of Cardiology, Hospital Universitario Clínico San Carlos, Madrid, Spain.

Miriam Juárez Fernández (M)

Department of Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Ana Viana-Tejedor (A)

Department of Cardiology, Hospital Universitario Clínico San Carlos, Madrid, Spain.

Carlos Ferrera (C)

Department of Cardiology, Hospital Universitario Clínico San Carlos, Madrid, Spain.

Pablo Salinas (P)

Department of Cardiology, Hospital Universitario Clínico San Carlos, Madrid, Spain - salinas.pablo@gmail.com.
Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain.

Classifications MeSH